Baillie Gifford & Co. Sells 1,350,066 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Baillie Gifford & Co. decreased its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 5.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,239,870 shares of the company's stock after selling 1,350,066 shares during the quarter. Baillie Gifford & Co. owned approximately 8.98% of Recursion Pharmaceuticals worth $166,331,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC bought a new stake in shares of Recursion Pharmaceuticals in the 3rd quarter valued at approximately $25,000. Farther Finance Advisors LLC raised its stake in shares of Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock worth $42,000 after acquiring an additional 4,091 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Recursion Pharmaceuticals by 1,588.4% in the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company's stock valued at $48,000 after purchasing an additional 6,036 shares in the last quarter. Amalgamated Bank raised its position in shares of Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company's stock worth $54,000 after acquiring an additional 2,459 shares during the last quarter. Finally, San Luis Wealth Advisors LLC acquired a new position in Recursion Pharmaceuticals during the 3rd quarter valued at about $69,000. Institutional investors and hedge funds own 89.06% of the company's stock.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 20,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $6.04, for a total value of $120,800.00. Following the completion of the sale, the chief executive officer now directly owns 762,656 shares in the company, valued at approximately $4,606,442.24. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, COO Tina Marriott sold 6,000 shares of the company's stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $7.56, for a total value of $45,360.00. Following the sale, the chief operating officer now owns 521,138 shares in the company, valued at $3,939,803.28. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Christopher Gibson sold 20,000 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total value of $120,800.00. Following the transaction, the chief executive officer now owns 762,656 shares of the company's stock, valued at $4,606,442.24. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 156,682 shares of company stock worth $1,012,618 over the last three months. 15.75% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts recently weighed in on RXRX shares. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, November 7th. Leerink Partners dropped their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a research report on Tuesday, September 3rd. Finally, Jefferies Financial Group cut their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a report on Tuesday, September 3rd. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and an average target price of $9.40.

Recursion Pharmaceuticals Price Performance

RXRX stock traded down $0.30 during trading on Tuesday, reaching $7.54. 4,424,500 shares of the company were exchanged, compared to its average volume of 5,711,893. The company has a 50-day moving average of $6.58 and a two-hundred day moving average of $7.62. The company has a market capitalization of $2.12 billion, a price-to-earnings ratio of -5.12 and a beta of 0.81. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 6.07. Recursion Pharmaceuticals, Inc. has a twelve month low of $5.22 and a twelve month high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The business had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals's revenue was up 147.6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.43) EPS. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.54 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.